We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.06B
1-Year Est. Return 215.32%
This Fund
S&P 500
This Quarter Est. Return
-18.54%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$1.69B
AUM Growth
-$959M
Cap. Flow
-$224M
Cap. Flow %
-13.27%
Top 10 Hldgs %
79.99%
Holding
63
New
4
Increased
11
Reduced
6
Closed
17

Top Buys

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$55M
2
ZYME icon
Zymeworks
ZYME
+$30.4M
3
AKRO
Akero Therapeutics
AKRO
+$18.7M
4
BEAM icon
Beam Therapeutics
BEAM
+$13.8M
5
QURE icon
uniQure
QURE
+$8.26M

Top Sells

Rank Stock Value
1
ARVN icon
Arvinas
ARVN
+$129M
2
SWTX
SpringWorks Therapeutics
SWTX
+$56.4M
3
THRD
Third Harmonic Bio
THRD
+$32.7M
4
NMRA icon
Neumora Therapeutics
NMRA
+$22M
5
CRGX
CARGO Therapeutics
CRGX
+$21.2M

Sector Composition

Rank Sector Weight
1 Healthcare 99.73%
2 Miscellaneous 0.27%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
APLS
1
DELISTED
Apellis Pharmaceuticals
APLS
$260M 15.43%
11,895,808
+4,965
+0% +$137K
JAZZ icon
2
Jazz Pharmaceuticals
JAZZ
$15.9B
$212M 12.57%
1,706,469
– –
ZYME icon
3
Zymeworks
ZYME
$2.02B
$206M 12.19%
17,259,548
+2,231,469
+15% +$30.4M
ANAB icon
4
AnaptysBio
ANAB
$1.67B
$146M 8.69%
7,880,094
+6,646
+0.1% +$111K
CRNX icon
5
Crinetics Pharmaceuticals
CRNX
$9B
$144M 8.53%
4,288,120
– –
PRTA icon
6
Prothena Corp
PRTA
$479M
$143M 8.5%
11,584,280
– –
SRPT icon
7
Sarepta Therapeutics
SRPT
$2.2B
$82.5M 4.89%
1,292,386
+522,386
+68% +$55M
XNCR icon
8
Xencor
XNCR
$1.94B
$65.4M 3.88%
6,144,767
– –
CRSP icon
9
CRISPR Therapeutics
CRSP
$5.58B
$47.3M 2.8%
1,389,276
– –
QURE icon
10
uniQure
QURE
$3.38B
$42.3M 2.51%
3,988,971
+588,971
+17% +$8.26M
JANX icon
11
Janux Therapeutics
JANX
$1.1B
$39.7M 2.35%
1,469,818
– –
IMNM icon
12
Immunome
IMNM
$3.13B
$27.5M 1.63%
4,079,415
+200,000
+5% +$1.92M
ETON icon
13
Eton Pharmaceutcials
ETON
$1.71B
$25.2M 1.49%
1,939,288
+109,685
+6% +$1.66M
MDGL icon
14
Madrigal Pharmaceuticals
MDGL
$12.3B
$24.8M 1.47%
75,000
– –
ORIC icon
15
Oric Pharmaceuticals
ORIC
$1.37B
$19.1M 1.13%
3,418,068
– –
AKRO
16
DELISTED
Akero Therapeutics
AKRO
$17.8M 1.06%
+440,000
New +$18.7M
KURA icon
17
Kura Oncology
KURA
$1.13B
$17.4M 1.03%
2,640,298
-916,971
-26% -$7.15M
TECX
18
Tectonic Therapeutic
TECX
$696M
$16.6M 0.98%
935,121
+85,978
+10% +$2.8M
RNAM
19
DELISTED
Avidity Biosciences
RNAM
$16.5M 0.98%
557,576
– –
NGNE icon
20
Neurogene
NGNE
$732M
$14.9M 0.88%
1,271,342
– –
TNGX icon
21
Tango Therapeutics
TNGX
$3.94B
$14.6M 0.86%
10,630,736
– –
VYGR icon
22
Voyager Therapeutics
VYGR
$218M
$13.2M 0.79%
3,917,546
– –
BEAM icon
23
Beam Therapeutics
BEAM
$3.03B
$10.3M 0.61%
+526,685
New +$13.8M
MBX
24
MBX Biosciences
MBX
$3.03B
$9.29M 0.55%
1,259,273
– –
DNA icon
25
Ginkgo Bioworks
DNA
$469M
$8.34M 0.49%
1,462,328
-281,016
-16% -$2.86M
1
2 3

Similar funds

RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
ST
Spinnaker Trust Portland, Maine $2.06B AUM 24.94% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return

EcoR1 Capital's Q1 2025 Portfolio in Review

As of Q1 2025, EcoR1 Capital held 63 positions worth $1.69B, down 36% from $2.65B the previous quarter. Its ten largest holdings account for 80% of the portfolio.

EcoR1 Capital withdrew a net $224M in Q1 2025, closing 17 positions and reducing 6 holdings. Its most notable exit was Arvinas, an estimated $129M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 95% a quarter earlier, followed by Miscellaneous.

Against the trend, EcoR1 Capital opened a new position in Akero Therapeutics worth $17.8M.

  • EcoR1 Capital's largest Q1 2025 buy was Akero Therapeutics: 440,000 shares worth $17.8M.
  • EcoR1 Capital added most to Sarepta Therapeutics in Q1 2025, an estimated $55M increase.
  • EcoR1 Capital's biggest Q1 2025 reduction was TScan Therapeutics, cutting an estimated $9.38M.
  • EcoR1 Capital fully exited Arvinas in Q1 2025, selling an estimated $129M.
  • EcoR1 Capital's ten largest holdings make up 80% of its $1.69B portfolio in Q1 2025.
  • EcoR1 Capital opened 4 new positions and closed 17 in Q1 2025.
  • EcoR1 Capital's portfolio value fell 36% quarter-over-quarter to $1.69B.

Based on EcoR1 Capital's 13F filing for Q1 2025, filed 15 May 2025.